Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Abobotulinum toxin A injection improves outcomes in paediatric patients with neurogenic bladder

06 Feb 2020

Paediatric patients with neurogenic bladder may benefit from intradetrusor abobotulinum toxin A, which has been shown to improve cystometric capacity and maximum neurogenic detrusor overactivity in a recent study. This effect persists over multiple injections.

Additionally, “[c]ompliance is significantly improved in patients with low compliance bladder vs overactive bladder,” the authors said.

Of the 30 patients included in this study, 15 (50 percent) received multiple abobotulinum toxin A injections. Sixteen patients (53 patients) had an overactive bladder.

Administration of abobotulinum toxin A led to significant improvements in cystometric capacity (p<0.0001) and maximum neurogenic detrusor overactivity (p=0.0001). No significant change was observed in compliance overall (p=0.25). Urodynamic parameters did not significantly differ between first and last abobotulinum toxin A injections.

Improvement was comparable between the low compliance and overactive bladder groups in terms of cystometric capacity (p=0.05) and maximum neurogenic detrusor overactivity (p=0.25). Moreover, compliance significantly improved in the low compliance group compared with the overactive bladder group (p=0.016).

In this study, the authors carried out a single-centre retrospective review of paediatric patients with neurogenic bladder treated with abobotulinum toxin A. They collected videourodynamic data on cystometric capacity, maximum neurogenic detrusor overactivity pressure and compliance before and after the first abobotulinum toxin A administration and after the last administration.

Patients were then divided into low compliance and overactive bladder groups based on initial videourodynamic findings. Videourodynamic outcomes before and after abobotulinum A injections were compared using paired t-test. Bladder groups were compared using the Mann-Whitney U test.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.